AbbVie Inc
ABBVToday
-1.44%
5 Days
+0.38%
1 Month
+5.16%
6 Months
+13.18%
Year to Date
+14.89%
1 Year
+24.40%
Recent
Analysis
Earnings
AbbVie Inc Stock (ABBV) Closed Up by 3.48% on Aug 18: Key Drivers Unveiled
• AbbVie successfully completed a multi-billion dollar debt offering to fund the Apogee acquisition. • Second-quarter revenue expanded by double digits, prompting an upgrade to full-year guidance. • Analysts issued Buy ratings with an average price target of $276.42.
Vertex Pharmaceuticals Inc Stock (VRTX) Opened Up by 9.76% on Aug 10: What Investors Need To Know
• Vertex reported positive Phase 3 data for its non-opioid pain treatment candidate. • The company raised its full-year revenue guidance following successful international product launches. • Analysts maintain a Buy rating with an average price target of $557.64.
Amgen Inc Stock (AMGN) Closed Up by 3.03% on Aug 4: Key Drivers Unveiled
• Amgen reported second-quarter earnings exceeding consensus estimates for revenue and earnings per share. • Positive interim clinical data for a metabolic health candidate drove share price appreciation. • Annual revenue reached $36.75 billion with the company ranking tenth in net profit.
Novo Nordisk A/S Stock (NVO) Moved Down by 8.75% on Jul 31: Key Drivers Unveiled
• Novo Nordisk shares declined following disappointing quarterly guidance and increased competitive pressure. • Rising operational costs and supply chain constraints are negatively impacting the company's margins. • Legislative uncertainty regarding U.S. drug pricing contributes to concerns over future revenue growth.
AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis
• Skyrizi and Rinvoq growth offset revenue losses from Humira biosimilar competition. • AbbVie raised its full-year adjusted earnings guidance following strong quarterly results. • Positive late-stage clinical trial data in neuroscience and oncology boosted mid-term growth.
Arrowhead Pharmaceuticals Inc Stock (ARWR) Closed Up by 19.04% on Jul 22: What Signal Does It Send?
• Arrowhead Pharmaceuticals shares rose following positive Phase 3 clinical trial results. • Analysts increased price targets based on successful clinical data and market potential. • Technical indicators currently provide sell signals despite recent positive fundamental developments.
AbbVie Inc's Score
Media Coverage
Analyst Rating
AbbVie Inc Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
AbbVie Inc Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.50% |
| BlackRock Institutional Trust Company, N.A. | 5.38% |
| State Street Investment Management (US) | 4.58% |
| Vanguard Portfolio Management, LLC | 2.80% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 45.09% |
| Investment Advisor/Hedge Fund | 21.63% |
| Research Firm | 3.14% |
| Bank and Trust | 2.36% |
Related Instruments
Popular Instruments
